Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.60 |
| ▸ | PPARG | P37231 | 4/20 | 0.60 |
| ▸ | PPARD | Q03181 | 4/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DHFR | P00374 | 3/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30025954 | 1.00 | KDM4E (0.62) | KDM4EFFAR1PPARGPPARDDRD2 | |
| SCHEMBL13348919 | 0.94 | KDM4E (0.59) | KDM4EFFAR1PPARGPPARDDRD2 | |
| SCHEMBL3728368 | 0.92 | KDM4E (0.61) | KDM4EFFAR1PPARGPPARDDRD2 | |
| SCHEMBL30025989 | 0.92 | KDM4E (0.61) | KDM4EFFAR1PPARGPPARDDRD2 | |
| SCHEMBL20591018 | 0.90 | KDM4E (0.60) | KDM4EFFAR1PPARGPPARDDRD2 | |
| SCHEMBL6846925 | 0.87 | KDM4E (0.58) | KDM4EFFAR1PPARGPPARDDRD2 | |
| SCHEMBL8389400 | 0.85 | KDM4E (0.61) | KDM4EFFAR1PPARGPPARDDRD2 | |
| SCHEMBL3947131 | 0.81 | CNR2 (0.58) | FFAR1DRD2DRD4DHFRFFAR4 | |
| SCHEMBL30639265 | 0.81 | PPARA (0.58) | FFAR1FFAR4 | |
| SCHEMBL523934 | 0.81 | LMNA (0.64) | KDM4EFFAR1PPARGPPARDRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-115947681-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| CN-109641844-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-112624997-A | Preparation method and application of 3-amino-2-oxazolidinone derivatives | 中国人民解放军军事科学院军事医学研究院 | 2021-04-09 | — | — | CN | disclosed |
| CN-112189008-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | KEMOTECH S.R.L. (IT) | 2014-11-20 | — | — | US | disclosed |
| EP-2789619-A1 | Pharmaceutical compounds wiht angiogenesis inbhibitory activity | Kemotech S.r.l. (IT) | 2014-10-15 | — | — | EP | disclosed |
| EP-2750678-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033228-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130017149-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| EP-2223914-A1 | Tricyclic condensed pyrazole derivatives as CB1 inhibitors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223913-A1 | Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-01 | — | — | EP | disclosed |
| US-20100215741-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KDM4E 4646/4885FFAR1 1632/4885PPARG 724/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KDM4E 4646/4885FFAR1 1632/4885PPARG 724/4885 |
| US-20140343294-A1 | PHARMACEUTICAL COMPOUNDS | CYP3A43, CYP2D6, CYP2C9 | KDM4E 2316/4885FFAR1 3829/4885PPARG 316/4885 |
| US-20100215741-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, CNR2, TRPV1 | KDM4E 2870/4885FFAR1 271/4885PPARG 12/4885 |
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | KDM4E 4305/4885FFAR1 4385/4885PPARG 2048/4885 |
| US-20130017149-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, CNR2, TRPV1 | KDM4E 2870/4885FFAR1 271/4885PPARG 12/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KDM4E 4646/4885FFAR1 1632/4885PPARG 724/4885 |
| US-20100216785-A1 | PHARMACEUTICAL COMPOSITIONS | CNR2, CNR1, SGMS2 | KDM4E 4335/4885FFAR1 76/4885PPARG 238/4885 |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KDM4E 4646/4885FFAR1 1632/4885PPARG 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.